Please check the following:
- {{x.value}}
FREE membership
FREE membership
Join Intelligent Investor today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
Log in
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Congratulations!
You now have free access to InvestSMART, we look forward to helping you on your financial journey.
You now have access to Free Eureka Report Insights, We look forward to helping you on your financial journey.
You now have access to Intelligent Investor Free Insights. We look forward to helping you build a market beating stock portfolio.
Looking for more…
Intelligent Investor Membership
15-day Free Trial
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
No thanks
Looking for more…
Eureka Report Membership
15-day Free Trial
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
No thanks
Cleo Diagnostics Ltd (ASX: COV) - Share Price and Research
- Current share price for COV : $0.200
Cleo Diagnostics Ltd (COV), an ASX-listed company, is a medical diagnostics/devices entity focussed on the development of non-invasive blood based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company has developed a three-phased product development strategy that will deliver three related tests for ovarian cancer detection which includes Triage Test, Recurrence Test and Screening Test.
COV General Information +
| ASX Code | COV |
| Website | http://www.cleodx.com |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 14 |
| COV Share Price | $0.200 |
| Day High | $0.000 |
| Day Low | $0.000 |
| Last Close | $0.200 |
| COV Share Price Movement | - ( No change ) |
Prices as at 16:40, 18 Apr 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
COV Related Research
Cleo Diagnostics Ltd (COV) Upcoming Dividends & Yields
There are no dividends for Cleo Diagnostics Ltd (COV). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Cleo Diagnostics Ltd (COV) Recent ASX Announcements
| Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
|---|---|---|---|---|---|
| COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials | 11 Apr 2024 9:31AM | $0.185 | $0.200 | $0.200 | risen by 8.11% |
| CLEO Appoints Partner to Commence U.S. Market Access Program | 2 Apr 2024 12:11PM | $0.170 | $0.200 | $0.200 | risen by 17.65% |
| Peer-Review Supports CLEOs Ovarian Cancer Detection Tech | 25 Mar 2024 9:45AM | $0.170 | $0.200 | $0.200 | risen by 17.65% |
- + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.
See all ASX announcements from Cleo Diagnostics Ltd (COV) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
COV Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2023A | -$1.73 | -$6.60 | 21,866.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2022A | -$0.04 | N2 | 0.00% | 0.00 | 0.00 | 0.00% | 0.0% |
COV Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2022 A | 2023 A | 2022 A | 2023 A | 2022 A | 2023 A | |||||
| Cochlear (COH) | $20,843M | 0.1063 | 0.3407 | 0.1157 | 68.7225 | 51.2596 | 45.9426 | 1.04% | 1.32% | 1.52% |
| Cleo Diagnostics (COV) | $15M | 218.6667 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Fisher & Paykel Hlth (FPH) | $14,366M | -0.3337 | 0.0134 | 0.3118 | 61.1180 | 60.3089 | 45.9727 | 1.66% | 1.33% | 1.47% |
| ResMed (RMD) | $17,929M | 0.1879 | 0.0960 | 0.1089 | 31.3130 | 28.5714 | 25.7650 | 0.71% | 0.95% | 1.05% |
COV Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | -9.52 | 0.00 |
| Market | 0.53 | 15.30 | 1.11 | 1.01 |
| Sector | 0.84 | 33.30 | 2.35 | 2.42 |
COV Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Richard Allman | Chief Executive Officer, Executive Director | 10 Oct 2022 |
| Dr Andrew Nicholas Stephens | Chief Scientific Officer, Executive Director | 19 Sep 2022 |
| Professor Thomas Jobling | Lead Medical Advisor, Non-Executive Director | 21 Dec 2022 |
| Mr Adrien Michele Wing | Non-Executive Chairman, Non-Executive Director | 11 Aug 2022 |
| Ms Lucinda Nolan | Non-Executive Director | 2 Mar 2023 |
Cleo Diagnostics Ltd (COV) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 14 Apr 2009 | MOORE, John | Transfer | Direct Shares | 209,420 | $0.054 | $11,308.680 |
| 14 Apr 2009 | MOORE, John | Buy | Indirect Shares | 40,760 | $0.054 | $2,201.040 |
| 18 Mar 2009 | MOORE, John | Buy | Direct Shares | 130,000 | $0.042 | $5,400.000 |
See all changes in directors' interest & trades for Cleo Diagnostics Ltd (COV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
COV Management
| Name | Position |
|---|---|
| Pauline M Moffatt | Company Secretary |
COV Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cleo Diagnostics Ltd (COV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 14,250,000 (11.09%) | Michelle Wing |
| 9,475,000 (7.37%) | Richard Vom |
| 7,500,000 (5.84%) | Hudson Institute Investment Holdings Pty Ltd |
COV Calendar of Events
| Date | Event |
|---|---|
| 27 February 2025 | Report (Interim) |
| 25 September 2024 | Report (Annual) |
| 29 August 2024 | Report (Prelim) |
FAQs about Cleo Diagnostics Ltd (COV)
What is the current share price of Cleo Diagnostics Ltd (COV)?
Cleo Diagnostics Ltd's (COV) current share price is $0.20. This constitutes a price movement of 0% when compared to the share price 7 days ago and is -6.98% below COV's 12-month high of $0.22 per share. Prices are delayed by at least 20 minutes.
What is the share price movement for Cleo Diagnostics Ltd (COV)?
Relative to the previous close share price of $0.20, Cleo Diagnostics Ltd's (COV) current share price of $0.20 constitutes a movement of or 0%. Cleo Diagnostics Ltd's (COV) share price movement is 0% when compared to 7 days ago and is -6.98% below COV's 52-week high of $0.22.
What is the 52-week high share price for Cleo Diagnostics Ltd (COV)?
Cleo Diagnostics Ltd's (COV) 52-week high is $0.22 which was reached on 1 Sep 2023. Relative to this, COV's current share price of $0.20 constitutes a -$0.02 or -6.98% drop since that high of $0.22 per COV share.
What is the 52-week low share price for Cleo Diagnostics Ltd (COV)?
Cleo Diagnostics Ltd's (COV) 52-week low is $0.14 which was reached on 30 Jan 2024. Relative to this, COV's current share price of $0.20 constitutes a $0.06 or 42.86% gain since that low of $0.14 per COV share.
What is the daily average trading volume for Cleo Diagnostics Ltd (COV)?
Over the last 12 months, Cleo Diagnostics Ltd (COV) has a daily average trading volume of 89,519 COV shares per day.
What is the dividend yield for Cleo Diagnostics Ltd (COV)?
Cleo Diagnostics Ltd (COV) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for COV is a ratio that tells you the percentage of Cleo Diagnostics Ltd's (COV) share price that it pays out in dividends each year.
When does Cleo Diagnostics Ltd (COV) release its next Annual Report?
Cleo Diagnostics Ltd (COV) will release its next Annual Report on 25 September 2024. Cleo Diagnostics Ltd's (COV) last annual report was released on 27 Sep 2023. Click here to view Cleo Diagnostics Ltd's (COV) last annual report.
In which sector is Cleo Diagnostics Ltd (COV) classified?
Cleo Diagnostics Ltd (COV) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Cochlear Limited (COH), and Fisher & Paykel Healthcare Corporation Limited (FPH).
What is the price-to-earnings (P/E) ratio for Cleo Diagnostics Ltd (COV)?
The price-to-earnings (P/E) ratio for Cleo Diagnostics Ltd (COV) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Cleo Diagnostics Ltd's (COV) share price to its earnings per COV share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
